CT
BEAM icon

Clearstead Trust’s Beam Therapeutics BEAM Stock Holding History

Clearstead Trust’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-125
Closed -$11K – 194
2021
Q3 		$11K Hold
125
– – 0.01% 163
2021
Q2 		$16K Buy
+125
New +$9.96K 0.01% 137
2021
Q1 		– Sell
-125
Closed -$10K – 107
2020
Q4 		$10K Buy
+125
New +$6.15K 0.01% 154

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Trust's BEAM Position: Q4 2021 in Review

Clearstead Trust sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 125 shares — an estimated $11K sold.

Clearstead Trust first reported a position in BEAM in Q4 2020 and held it in 3 quarters. The position peaked at $16K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Clearstead Trust reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Clearstead Trust sold 125 Beam Therapeutics shares in Q4 2021, an estimated $11K.
  • Clearstead Trust first reported a position in Beam Therapeutics in Q4 2020 and held it in 3 quarters.
  • Clearstead Trust's Beam Therapeutics position peaked at $16K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Clearstead Trust's 13F filing for Q4 2021, filed 9 Feb 2022.